Beatriz Silva Lima

Beatriz Silva Lima

Auto-generated profile, based on publicly available information

Beatriz Silva Lima

Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2010 in Nature Biotechnology
Verified
Journal Article
Closed access
FDFrank Dieterle
Frank Dieterle
FSFrank Sistare
Frank Sistare
FGFederico Goodsaid
Federico Goodsaid
MPMarisa Papaluca
Marisa Papaluca
JOJosef S Ozer
Josef S Ozer
WMWilliam Mattes
William Mattes

6 October 2014 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
JRJoão Rocha
João Rocha
MFMaria Eduardo Figueira
Maria Eduardo Figueira
ABAndreia Barateiro
Andreia Barateiro
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes
Dora BritesDora Brites
Dora Brites
BSBruno Sepodes
Bruno Sepodes
Rosmarinic acid is a polyphenolic compound and main constituent ofRosmarinus officinalisand has been shown to possess antioxidant and anti‐inflammatory properties. We aimed to evaluate the anti‐inflammatory properties of rosmarinic acid and of an extract ofR. officinalisin local inflammation (carrageenin‐induced paw oedema model in the rat), and further evaluate the protective effect of rosmarinic acid in rat models of systemic inflammation: liver ischaemia–reperfusion (I/R) and thermal injury models. In the local inflammation model, rosmarinic acid was administered at 10, 25 and 50 mg/kg (p.o.), and the extract was administered at 10 and 25 mg/kg (equivalent doses to rosmarinic acid groups) to male Wistar rats. Administration of rosmarinic acid and extract at the dose of 25 mg/kg reduced paw oedema at 6 hr by over 60%, exhibiting a dose–response effect, suggesting that rosmarinic was the main contributor to the anti‐inflammatory effect. In the liver I/R model, rosmarinic acid was administered at 25 mg/kg (i.v.) 30 min. prior to the induction of ischaemia and led to the significant reduction in the serum concentration of transaminases (ASTandALT) andLDH. In the thermal injury model, rosmarinic acid was administered at 25 mg/kg (i.v.) 5 min. prior to the induction of injury and significantly reduced multi‐organ dysfunction markers (liver, kidney, lung) by modulatingNF‐κB and metalloproteinase‐9. For the first time, the anti‐inflammatory potential of rosmarinic acid has been identified, as it causes a substantial reduction in inflammation, and we speculate that it might be useful in the pharmacological modulation of injuries associated to inflammation.

9 May 2013 in Nanomedicine
Verified
Journal Article
Closed access
FEFalk Ehmann
Falk Ehmann
KSKumiko Sakai-Kato
Kumiko Sakai-Kato
RDRuth Duncan
Ruth Duncan
DODolores Hernán Pérez de la Ossa
Dolores Hernán Pérez de la Ossa
RPRuben Pita
Ruben Pita
MAMarisa Papaluca Amati
Marisa Papaluca Amati
Over the last three decades many first-generation nanomedicines have successfully entered routine clinical use and it is now important for medicines regulatory agencies to consider the mechanisms needed to ensure safe introduction of 'follow-on' nanomedicine products, 'nanosimilars'. Moreover, drug regulators need to ensure that 'next'-generation nanomedicines enter clinical development and consequently the market in a safe and timely way for the benefit of public health. Here we review recent European Medicines Agency activities that relate to the effective development and evaluation of nanomedicine products while keeping patient and consumer safety at the forefront.

1 September 2013 in mAbs
Verified
Journal Article
Open access
PDF file
PMPeter J.K. van Meer
Peter J.K. van Meer
MKMarlous Kooijman
Marlous Kooijman
VBVera Brinks
Vera Brinks
CWChristine C. Gispen-De Wied
Christine C. Gispen-De Wied
BSBeatriz Silva-Lima
Beatriz Silva-Lima
HSHuub Schellekens
Huub Schellekens
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved challenge in drug development. Non-human primates (NHPs) are often the only relevant animal model for the development of monoclonal antibodies (mAbs), but the immune response of NHPs to therapeutic mAbs is not considered to be predictive of the response in humans because of species differences. In this study, we accessed the drug registration files of all mAbs registered in the European Union to establish the relative immunogenicity of mAbs in NHPs and humans. The incidence of formation of antidrug-antibodies in NHPs and patients was comparable in only 59% of the cases. In addition, the type of antidrug-antibody response was different in NHP and humans in 59% of the cases. Humanization did not necessarily reduce immunogenicity in humans. Immunogenicity interfered with the safety assessment during non-clinical drug development when clearing or neutralizing antibodies were formed. While important to interpret the study results, immunogenicity reduced the quality of NHP data in safety assessment. These findings confirm that the ability to compare relative immunogenicity of mAbs in NHPs and humans is low. Furthermore, immunogenicity limits the value of informative NHP studies.

1 December 2017 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
RBRoland Buesen
Roland Buesen
BCBrian N. Chorley
Brian N. Chorley
BLBeatriz da Silva Lima
Beatriz da Silva Lima
GDGeorge Daston
George Daston
LDLize Deferme
Lize Deferme
APAlan Poole
Alan Poole
Prevailing knowledge gaps in linking specific molecular changes to apical outcomes and methodological uncertainties in the generation, storage, processing, and interpretation of 'omics data limit the application of 'omics technologies in regulatory toxicology. Against this background, the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) convened a workshop Applying 'omics technologies in chemicals risk assessment that is reported herein. Ahead of the workshop, multi-expert teams drafted frameworks on best practices for (i) a Good-Laboratory Practice-like context for collecting, storing and curating 'omics data; (ii) the processing of 'omics data; and (iii) weight-of-evidence approaches for integrating 'omics data. The workshop participants confirmed the relevance of these Frameworks to facilitate the regulatory applicability and use of 'omics data, and the workshop discussions provided input for their further elaboration. Additionally, the key objective (iv) to establish approaches to connect 'omics perturbations to phenotypic alterations was addressed. Generally, it was considered promising to strive to link gene expression changes and pathway perturbations to the phenotype by mapping them to specific adverse outcome pathways. While further work is necessary before gene expression changes can be used to establish safe levels of substance exposure, the ECETOC workshop provided important incentives towards achieving this goal.

10 May 2010 in Nature Biotechnology
Verified
Journal Article
Closed access
FSFrank D Sistare
Frank D Sistare
FDFrank Dieterle
Frank Dieterle
STSean Troth
Sean Troth
DHDaniel J Holder
Daniel J Holder
DGDavid Gerhold
David Gerhold
YYYan Yu
Yan Yu